| 04.14.23 | Biotech's top money raisers; Amgen CEO's big payday; Biotech leaders not staying quiet after abortion pill ruling

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

1 jahr vor

Html
Text

Weekly Digest

Deep learning methods reveal hidden patterns to improve rare disease detection.

Improve patient pattern characterization, classification and augmentation. Download: CONAN - Complementary pattern augmentation for rare disease detection.

This Week

Apr 14, 2023

SPECIAL REPORT—Biotech's top money raisers of 2022

After 2022's M&A spree, Amgen CEO Robert Bradway collects $21.4M payday

Biotech leaders 'cannot stay quiet' as judge blocks abortion pill approval

A discovery of how cells select their identity had researchers 'dancing around the lab'

After last year's cuts, Biogen kicks off another round of layoffs

Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus

Theranos' Elizabeth Holmes must report to prison this month despite pending appeal, judge rules

Philips re-recalls 1,200 CPAP, BiPAP machines repaired in far-reaching ventilator probe

AbbVie, J&J pull 2 Imbruvica accelerated approvals in lymphoma, giving way to AZ and BeiGene

Genentech probe of Marc Tessier-Lavigne paper finds no fraud evidence, but image 'anomalies' stay unresolved

After telegraphing layoffs last month, J&J secures $14M sale of consumer health plant in Pennsylvania

Fierce Medical Affairs Strategic Summit

May 1 - 3, 2023 | Jersey City, NJ

Connect on current challenges and opportunities found within your medical affairs role to become better equipped in developing a unified scientific voice.
Register Today!

Featured

Biotech's top money raisers of 2022

By Gabrielle Masson

Nothing good lasts forever, a sentiment that held true for private biotech financing in 2022. After two record-setting years, fundraises finally fell, dipping 24% from the highs of 2021.

After 2022's M&A spree, Amgen CEO Robert Bradway collects $21.4M payday

By Zoey Becker

In a slight decrease from 2021, Amgen's M&A-hungry CEO Robert Bradway collected $21.4 million in total pay last year.

Biotech leaders 'cannot stay quiet' as judge blocks abortion pill approval

By Annalee Armstrong

Some 300 biotech executives and industry leaders are objecting to the decision from a Texas federal judge to block the FDA’s approval of the abortion drug mifepristone. The executives argue that the judicial interference will undermine the agency’s authority and endanger innovation in the industry.

A discovery of how cells select their identity had researchers 'dancing around the lab'

By Annalee Armstrong

A cell has to know what it is to do its job. New research from Trinity College Dublin has helped reveal just how cells establish their identities, which could have implications for developing more targeted cancer treatments.


A message from Digital Pharma Innovation Week

After last year's cuts, Biogen kicks off another round of layoffs

By Zoey Becker

After a round of layoffs last year, Biogen is axing positions once again. This time, the company is reportedly targeting employees on its multiple sclerosis team.

Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus

By Kevin Dunleavy

Four months after filing for bankruptcy, Clovis Oncology has found a buyer for its assets including the rights to ovarian cancer drug Rubraca. Pharma& Schweiz GmbH of Switzerland submitted the highest bid at an auction on March 30. The agreement is for $70 million up front, with an additional $50 million on achieving regulatory milestones and $15 million in sales-related milestones.

Theranos' Elizabeth Holmes must report to prison this month despite pending appeal, judge rules

By Andrea Park

Elizabeth Holmes must report to prison at the end of this month as previously scheduled, the judge in her case ruled this week, shutting down the disgraced Theranos founder’s bid to delay her sentence while she appeals her conviction.

Philips re-recalls 1,200 CPAP, BiPAP machines repaired in far-reaching ventilator probe

By Andrea Park

In a classic “two steps forward, one step back” situation, just as Philips is aiming to wrap up the repair-and-replace program for the 5.5 million respiratory devices it began recalling two years ago, the company has had to re-recall a slew of the already repaired machines.

AbbVie, J&J pull 2 Imbruvica accelerated approvals in lymphoma, giving way to AZ and BeiGene

By Angus Liu

AbbVie and J&J are pulling two Imbruvica accelerated approvals after failing to satisfy the FDA. They're doing so even though the drug met its primary endpoint in a confirmatory trial in one of the indications.

Genentech probe of Marc Tessier-Lavigne paper finds no fraud evidence, but image 'anomalies' stay unresolved

By Nick Paul Taylor

Genentech has published the findings of its investigation into an alleged fraud and a cover-up involving a 2009 Nature paper co-authored by Marc Tessier-Lavigne. None of the 35 current and former employees interviewed for the probe reported knowing of fraud, but the process did leave unanswered questions.

After telegraphing layoffs last month, J&J secures $14M sale of consumer health plant in Pennsylvania

By Fraiser Kansteiner

After decades under Johnson & Johnson, a massive plant that once cranked out over-the-counter mainstays like Pepcid and Imodium is poised to hit the market.

Fierce podcasts

Don't miss an episode

'The Top Line': The biotechs that scored top VC dollars in 2022, plus this week's headlines

This week on "The Top Line," we talk about biotech’s top money raisers in 2022. We also cover J&J's talc litigation, prison plans for Elizabeth Holmes and more of this week's top headlines.

'Podnosis': Medicaid's outlook as redetermination gets underway, and how stakeholders can tackle colorectal cancer

'The Top Line': Humira's patent cliff and 2023's other big patent expirations, plus this week's headlines

'Podnosis': Tackling adolescent mental health, and how inflation and labor shortages will play out in Medicare Advantage

Webinar: In Silico Trial Design in Development of Rare Disease Cell and Gene Therapies

Thursday, April 20, 2023 | 11am ET / 8am PT

In this presentation, we highlight key study design challenges and considerations for rare disease CGT trials and discuss the potential for leveraging in silico approaches for generating synthetic control arms that enable a control-based comparative assessment of efficacy. Register now.

Resources

Whitepaper

Accelerated Approval Pathways Pose Commercialization Risk

Accelerated approval pathways create an additional layer of complexity in the chaotic oncology marketplace, leaving manufacturers of all sizes seeking a new commercialization model for launch success.

The Hematopoietic Colony Forming Cell (CFC) Assay for Drug Safety and Toxicity

The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process

Sponsored by: ReachBio | The Cell Biology Experts™

Whitepaper

Accessing and Analyzing Relevant Content in Today’s Information Chaos – R&D Challenges and Opportunities

We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing?

Three Considerations to Expand Physicians’ Bandwidth and Improve Real-World Safety Reporting

The current real-world safety reporting process is too burdensome for most HCPs – how can technology help?

Blueprint for Commercializing Cell and Gene Therapies

How advanced medicines commercial readiness differs and the resources needed to maximize potential.

Coming to America: Keys to Success for ex-US Digital Health Companies Entering the US Market

This paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.

Sponsored by: Thermo Scientific Production Chemicals and Services

Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.